Los Angeles Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Los Angeles Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.79M	Sell	509,247 -125,084	-20%	-$513K	0.01%	530
2025 Q4	$951K	Sell	634,331 -495,721	-44%	-$1.29M	﹤0.01%	642
2025 Q3	$1.48M	Sell	1,130,052 -81,103	-7%	-$83.9K	0.01%	589
2025 Q2	$869K	Buy	1,211,155 +523,368	+76%	+$411K	﹤0.01%	688
2025 Q1	$1.01M	Buy	687,787 +356,087	+107%	+$848K	﹤0.01%	564
2024 Q4	$1.47M	Buy	331,700 +319,528	+2,625%	+$1.3M	0.01%	509
2024 Q3	$50.1K	Sell	12,172 -24,674	-67%	-$133K	﹤0.01%	1150
2024 Q2	$240K	Sell	36,846 -48,497	-57%	-$343K	﹤0.01%	1083
2024 Q1	$743K	Buy	85,343 +57,806	+210%	+$701K	﹤0.01%	774
2023 Q4	$315K	Sell	27,537 -22,978	-45%	-$227K	﹤0.01%	1006
2023 Q3	$486K	Sell	50,515 -164,146	-76%	-$1.61M	﹤0.01%	830
2023 Q2	$2.28M	Buy	214,661 +22,105	+11%	+$238K	0.01%	461
2023 Q1	$2.03M	Sell	192,556 -8,789	-4%	-$98.5K	0.01%	498
2022 Q4	$2.49M	Buy	201,345 +48,037	+31%	+$545K	0.01%	463
2022 Q3	$1.59M	Buy	153,308 +93,835	+158%	+$1.06M	0.01%	563
2022 Q2	$686K	Hold	59,473	–	–	﹤0.01%	851
2022 Q1	$748K	Hold	59,473	–	–	﹤0.01%	875
2021 Q4	$693K	Sell	59,473 -674	-1%	-$8.27K	﹤0.01%	863
2021 Q3	$786K	Buy	60,147 +2,360	+4%	+$30.5K	﹤0.01%	856
2021 Q2	$744K	Sell	57,787 -3,255	-5%	-$37.3K	﹤0.01%	992
2021 Q1	$682K	Sell	61,042 -81,300	-57%	-$859K	﹤0.01%	1079
2020 Q4	$1.62M	Sell	142,342 -898	-0.6%	-$9.83K	0.01%	738
2020 Q3	$1.29M	Sell	143,240 -14,018	-9%	-$139K	0.01%	725
2020 Q2	$1.62M	Buy	157,258 +5,482	+4%	+$56.1K	0.01%	680
2020 Q1	$1.53M	Buy	151,776 +29,095	+24%	+$342K	0.01%	608
2019 Q4	$1.63M	Buy	122,681 +45,584	+59%	+$503K	0.01%	698
2019 Q3	$662K	Hold	77,097	–	–	﹤0.01%	912
2019 Q2	$843K	Buy	77,097 +14,111	+22%	+$158K	﹤0.01%	892
2019 Q1	$714K	Buy	+62,986	New	+$703K	﹤0.01%	975
2018 Q3	–	Sell	-19,480	Closed	-$312K	–	1431
2018 Q2	$312K	Sell	19,480 -30,811	-61%	-$456K	﹤0.01%	1274
2018 Q1	$650K	Buy	+50,291	New	+$627K	﹤0.01%	954

Other funds holding IRWD

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Los Angeles Capital Management's IRWD Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Ironwood Pharmaceuticals (IRWD) stake by 20% in Q1 2026, selling an estimated $513K and leaving 509,247 shares worth $1.79M. The position accounts for 0.01% of the portfolio, ranked #530.

Los Angeles Capital Management first reported a position in IRWD in Q1 2018 and has held it in 31 quarters since. The position peaked at $2.49M in Q4 2022. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

Los Angeles Capital Management held 509,247 shares of Ironwood Pharmaceuticals worth $1.79M as of Q1 2026.
Los Angeles Capital Management sold 125,084 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $513K.
Ironwood Pharmaceuticals made up 0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #530 holding.
Los Angeles Capital Management first reported a position in Ironwood Pharmaceuticals in Q1 2018 and has held it in 31 quarters since.
Los Angeles Capital Management's Ironwood Pharmaceuticals position peaked at $2.49M in Q4 2022.
226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.